Chemotherapeutic agents and the skin: An update

Journal of the American Academy of Dermatology

Volumn 58, Issue 4, 2008, Pages 545-570

  Heidary, Noushin ^a   Naik, Haley ^b   Burgin, Susan ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CETUXIMAB; CLINDAMYCIN; CORTICOSTEROID; DASATINIB; DIPHENHYDRAMINE; DOCETAXEL; DOXYCYCLINE; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; HYDROXYZINE; IMATINIB; IMC 225; IRINOTECAN; ISOTRETINOIN; LYMECYCLINE; METRONIDAZOLE; MINOCYCLINE; MUCIPROCIN; NILOTINIB; PANITUMUMAB; RETINOIC ACID; SORAFENIB; SUNITINIB; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ACNE; ACTINIC KERATOSIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALLERGIC REACTION; ALOPECIA; B CELL LYMPHOMA; BLEPHARITIS; BREAST CANCER; BULLOUS DERMATITIS; BULLOUS SKIN DISEASE; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; DEPIGMENTATION; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; EPIPHORA; ERYTHEMA; ERYTHEMA NODOSUM; EYE IRRITATION; EYE TOXICITY; FIBROSARCOMA; FLUSHING; FOLLICULITIS; GASTROINTESTINAL STROMAL TUMOR; HAIR GROWTH; HAND FOOT SYNDROME; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERHIDROSIS; HYPERKERATOSIS; HYPERPIGMENTATION; HYPOPIGMENTATION; INJECTION SITE REACTION; INTESTINAL BLEEDING; KAPOSI SARCOMA; LICHENOID ERUPTION; LUNG ALVEOLITIS; LUNG NON SMALL CELL CANCER; MASTOCYTOSIS; MEASLES LIKE RASH; METAPLASIA; MONOTHERAPY; MUCINOSIS; MYALGIA; MYCOSIS FUNGOIDES; NAIL DYSTROPHY; NAUSEA; PANCREAS CANCER; PANNICULITIS; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOSPHORYLATION; PHOTOSENSITIVITY; PITYRIASIS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUSTULE; PUSTULOSIS; PYOGENIC GRANULOMA; RASH; RETINA EDEMA; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; SKIN ULCER; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; STOMATITIS; TELANGIECTASIA; TRANSIENT ACANTHOLYTIC DERMATOSIS; TREATMENT RESPONSE; URTICARIA; VAGINAL DRYNESS; VAGINAL PRURITUS; VASCULITIS; XEROSIS;

EID: 40649091391     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.01.001     Document Type: Review

References (299)

1. W.S. Susser D.L. Whitaker-Worth J.M. Grant-Kels Mucocutaneous reactions to chemotherapy J Am Acad Dermatol 40 1999 367 398
2. M. Tiseo M. Loprevite A. Ardizzoni Epidermal growth factor receptor inhibitors: A new prospective in the treatment of lung cancer Curr Med Chem Anticancer Agents 4 2004 139 148
3. G. Blackledge S. Averbuch Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors Br J Cancer 90 2004 566 572
4. T.J. Lynch D.W. Bell R. Sordella S. Gurubhagavatula R.A. Okimoto B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
5. R. Van Doorn G. Kirtschig E. Scheffer T.J. Stoof G. Giaccone Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor Br J Dermatol 147 2002 598 601
6. R.S. Herbst A.M. Maddox M.L. Rothenberg E.J. Small E.H. Rubin J. Baselga Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial J Clin Oncol 20 2002 3815 3825
7. M.G. Kris R.B. Natale R.S. Herbst T.J. Lynch Jr. D. Prager C.P. Belani Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial JAMA 290 2003 2149 2158
8. E.E. Cohen F. Rosen W.M. Stadler W. Recant K. Stenson D. Huo Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 2003 1980 1987
9. R. Perez-Soler Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 17 11 suppl. 12 2003 23 28
10. M. Harris Monoclonal antibodies as therapeutic agents for cancer Lancet Oncol 5 2004 292 302
11. M.N. Needle Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody Semin Oncol 29 5 suppl. 14 2002 55 60
12. S.M. Thomas J.R. Grandis Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation Cancer Treat Rev 30 2004 255 268
13. M. Fukuoka S. Yano G. Giaccone T. Tamura K. Nakagawa J.Y. Douillard Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2003 2237 2246
14. A.L. Agero S.W. Dusza C. Benvenuto-Andrade K.J. Busam P. Myskowski A.C. Halpern Dermatologic side effects associated with the epidermal growth factor receptor inhibitors J Am Acad Dermatol 55 2006 657 670
15. K.J. Busam P. Capodieci R. Motzer T. Kiehn D. Phelan A.C. Halpern Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 Br J Dermatol 144 2001 1169 1176
16. M. Fernandez-Galar A. Espana J.M. Lopez-Picazo Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor Clin Exp Dermatol 29 2004 138 140
17. W. Jacot D. Bessis E. Jorda M. Ychou M. Fabbro J.L. Pujol Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours Br J Dermatol 151 2004 238 241
18. C. Robert J.C. Soria A. Spatz A. Le Cesne D. Malka P. Pautier Cutaneous side-effects of kinase inhibitors and blocking antibodies Lancet Oncol 6 2005 491 500
19. S. Segaert E. Van Cutsem Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann Oncol 16 2005 1425 1433
20. E. Roe M.P. Garcia Muret E. Marcuello J. Capdevila C. Pallares A. Alomar Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients J Am Acad Dermatol 55 2006 429 437
21. R.S. Herbst P.M. LoRusso M. Purdom D. Ward Dermatologic side effects associated with gefitinib therapy: Clinical experience and management Clin Lung Cancer 4 2003 366 369
22. A. Kimyai-Asadi M.H. Jih Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors Arch Dermatol 2138 2002 129 131
23. X. Wu M. Rubin Z. Fan T. DeBlasio T. Soos A. Koff Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody Oncogene 12 1996 1397 1403
24. A. Sanz M.L. del Valle A man whose scapula was spared a drug-associated rash CMAJ 172 2005 745
25. S.S. Mitra R. Simcock Erlotinib induced skin rash spares skin in previous radiotherapy field J Clin Oncol 24 2006 e28 e29
26. P. Matheis M.A. Socinski C. Burkhart S. Warren N.E. Thomas Treatment of gefitinib-associated folliculitis J Am Acad Dermatol 55 2006 710 713
27. E. Molinari J. De Quatrebarbes T. Andre S. Aractingi Cetuximab-induced acne Dermatology 211 2005 330 333
28. R. Gutzmer T. Werfel R. Mao A. Kapp J. Elsner Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy Br J Dermatol 153 2005 849 851
29. T. Micantonio M.C. Fargnoli E. Ricevuto C. Ficorella P. Marchetti K. Peris Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy Arch Dermatol 141 2005 1173 1174
30. R. Perez-Soler L. Saltz Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 23 2005 5235 5246
31. R. Perez-Soler A. Chachoua L.A. Hammond E.K. Rowinsky M. Huberman D. Karp Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer J Clin Oncol 22 2004 3238 3247
32. D. Soulieres N.N. Senzer E.E. Vokes M. Hidalgo S.S. Agarwala L.L. Siu Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 2004 77 85
33. J. Baselga The EGFR as a target for anticancer therapy—Focus on cetuximab Eur J Cancer 37 suppl 4 2001 S16 S22
34. D. Cunningham Y. Humblet S. Siena D. Khayat H. Bleiberg A. Santoro Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
35. A.R. Tan X. Yang S.M. Hewitt A. Berman E.R. Lepper A. Sparreboom Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor J Clin Oncol 22 2004 3080 3090
36. J. Baselga J. Trigo J. Bourhis Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen (abstract) Proc Am Soc Clin Oncol 21 2002 226a
37. M. Kies M. Arquette L. Nabell Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225) in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy (abstract) Proc Am Soc Clin Oncol 21 2002 232A
38. Saltz L, Rubin MS, Hochster H. Acne-like rash predicts response in patients treated with Cetuximab (IMC-C225) plus Irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). In: American Association for Cancer Research/National Cancer Institute/European Organization for Research and Treatment of Cancer International Conference; 2001.
39. F.A. Shepherd J. Pereira T.E. Ciuleanu A randomized placebo-controlled trial of erlotinib in patients with advanced nonsmall cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy: A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial (abstract) Proc Am Soc Clin Oncol 23 2004 622
40. G. Tonini B. Vincenzi D. Santini D. Olzi A. Lambiase S. Bonini Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient J Natl Cancer Inst 97 2005 606 607
41. G.C. Chang T.Y. Yang K.C. Chen M.C. Yin R.C. Wang Y.C. Lin Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 2004 4646 4648
42. T. Dainichi M. Tanaka N. Tsuruta M. Furue K. Noda Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor Dermatology 207 2003 324 325
43. M.W. Lee C.W. Seo S.W. Kim H.J. Yang H.W. Lee J.H. Choi Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor Acta Derm Venereol 84 2004 23 26
44. J. Nakano M. Nakamura Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor J Dermatol 30 2003 261 262
45. K.W. Boucher K. Davidson B. Mirakhur J. Goldberg W.R. Heymann Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody J Am Acad Dermatol 47 2002 632 633
46. M. Monti L.L. Mancini B. Ferrari D. Rahal A. Santoro Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab J Clin Oncol 21 2003 4651 4653
47. K.Y. Shu H.L. Kindler M. Medenica M. Lacouture Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab Br J Dermatol 154 2006 191 192
48. J.E. Graves B.F. Jones A.C. Lind M.P. Heffernan Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib J Am Acad Dermatol 55 2006 349 353
49. C. Montagut J.J. Grau R. Grimalt J. Codony J. Ferrando J. Albanell Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab J Clin Oncol 23 2005 5273 5275
50. O. Bouche H. Brixi-Benmansour A. Bertin G. Perceau S. Lagarde Trichomegaly of the eyelashes following treatment with cetuximab Ann Oncol 16 2005 1711 1712
51. S. Dueland T. Sauer F. Lund-Johansen B. Ostenstad K.M. Tveit Epidermal growth factor receptor inhibition induces trichomegaly Acta Oncol 42 2003 345 346
52. J.C. Pascual J. Banuls I. Belinchon M. Blanes B. Massuti Trichomegaly following treatment with gefitinib (ZD1839) Br J Dermatol 151 2004 1111 1112
53. M.E. Lacouture A. Desai K. Soltani V. Petronic-Rosic A.E. Laumann M.J. Ratain Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor Clin Exp Dermatol 31 2006 783 785
54. S.F. Wong Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer Clin Ther 27 2005 684 694
55. R.M. Giusti K.A. Shastri M.H. Cohen P. Keegan R. Pazdur FDA drug approval summary: Panitumumab (Vectibix) Oncologist 12 2007 577 583
56. J. Riddle P. Lee M. Purdom The epidermal growth factor receptor as a novel target for cancer therapy: Case studies and clinical implications Semin Oncol Nurs 18 4 suppl. 4 2002 11 19
57. I. Kurokawa K. Endo M. Hirabayashi Purpuric drug eruption possibly due to gefinitib (Iressa) Int J Dermatol 44 2005 167 168
58. M.P. Zorzou A. Stratigos E. Efstathiou A. Bamias Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor Acta Derm Venereol 84 2004 308 309
59. A. Trojan E. Jacky F. Follath R. Dummer Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition Swiss Med Wkly 133 2003 22 23
60. G.G. Tscharner S. Buhler M. Borner T. Hunziker Grover's disease induced by cetuximab Dermatology 213 2006 37 39
61. G. McArthur Molecularly targeted treatment for dermatofibrosarcoma protuberans Semin Oncol 31 2 suppl. 6 2004 30 36
62. J. Cools D.J. DeAngelo J. Gotlib E.H. Stover R.D. Legare J. Cortes A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N Engl J Med 348 2003 1201 1214
63. J.F. Apperley M. Gardembas J.V. Melo R. Russell-Jones B.J. Bain E.J. Baxter Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta N Engl J Med 347 2002 481 487
64. H.B. Koon G.J. Bubley L. Pantanowitz D. Masiello B. Smith K. Crosby Imatinib-induced regression of AIDS-related Kaposi's sarcoma J Clin Oncol 23 2005 982 989
65. A. Pardanani Systemic mastocytosis: Bone marrow pathology, classification, and current therapies Acta Haematol 114 2005 41 51
66. E.C. McGary A. Onn L. Mills A. Heimberger O. Eton G.W. Thomas Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo J Invest Dermatol 122 2004 400 405
67. K. Wyman M.B. Atkins V. Prieto O. Eton D.F. McDermott F. Hubbard Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy Cancer 106 2006 2005 2011
68. B.J. Druker M. Talpaz D.J. Resta B. Peng E. Buchdunger J.M. Ford Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
69. M. Talpaz R.T. Silver B.J. Druker J.M. Goldman C. Gambacorti-Passerini F. Guilhot Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study Blood 99 2002 1928 1937
70. H. Kantarjian C. Sawyers A. Hochhaus F. Guilhot C. Schiffer C. Gambacorti-Passerini Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 2002 645 652
71. A. Drummond P. Micallef-Eynaud W.S. Douglas I. Hay T.L. Holyoake M.W. Drummond A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec) Br J Haematol 120 2003 911 913
72. L. Valeyrie S. Bastuji-Garin J. Revuz N. Bachot J. Wechsler P. Berthaud Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients J Am Acad Dermatol 48 2003 201 206
73. K. Pietras A. Ostman M. Sjoquist E. Buchdunger R.K. Reed C.H. Heldin Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors Cancer Res 61 2001 2929 2934
74. B. Esmaeli R. Diba M.A. Ahmadi H.G. Saadati M.M. Faustina T.R. Shepler Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec) Eye 18 2004 760 762
75. E. Kusumi A. Arakawa M. Kami D. Kato K. Yuji Y. Kishi Visual disturbance due to retinal edema as a complication of imatinib Leukemia 18 2004 1138 1139
76. L.T. Hsiao H.M. Chung J.T. Lin T.J. Chiou J.H. Liu F.S. Fan Stevens–Johnson syndrome after treatment with STI571: A case report Br J Haematol 117 2002 620 622
77. S.A. Rule S.G. O'Brien L.C. Crossman Managing cutaneous reactions to imatinib therapy Blood 100 2002 3434 3435
78. G. Severino C. Chillotti R. De Lisa M. Del Zompo R. Ardau Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors Ann Pharmacother 39 2005 162 164
79. D. Vidal L. Puig A. Sureda A. Alomar Sti571-induced Stevens–Johnson syndrome Br J Haematol 119 2002 274 275
80. K. Pavithran M. Thomas Imatinib induced Stevens–Johnson syndrome: Lack of recurrence following re-challenge with a lower dose Indian J Dermatol Venereol Leprol 71 2005 288 289
81. B. Sanchez-Gonzalez J.C. Pascual-Ramirez P. Fernandez-Abellan I. Belinchon-Romero C. Rivas G. Vegara-Aguilera Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia Blood 101 2003 2446
82. M.C. Brouard C. Prins S. Mach-Pascual J.H. Saurat Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia Dermatology 203 2001 57 59
83. M. Schwarz K.A. Kreuzer G. Baskaynak B. Dorken P. le Coutre Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia Eur J Haematol 69 2002 254 256
84. E. Gambillara E. Laffitte N. Widmer L.A. Decosterd M.A. Duchosal T. Kovacsovics Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia Dermatology 211 2005 363 365
85. P. Raanani J.M. Goldman I. Ben-Bassat Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571 J Clin Oncol 20 2002 869 870
86. A.S. Tsao H. Kantarjian J. Cortes S. O'Brien M. Talpaz Imatinib mesylate causes hypopigmentation in the skin Cancer 98 2003 2483 2487
87. B. Arora L. Kumar A. Sharma J. Wadhwa V. Kochupillai Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate Ann Oncol 15 2004 358 359
88. K.W. Leong T.C. Lee A.S. Goh Imatinib mesylate causes hypopigmentation in the skin Cancer 100 2004 2486 2487
89. S. McPartlin M. Leach Loss of skin pigment caused by imatinib therapy Br J Haematol 129 2005 448
90. P. Rousselot J. Larghero E. Raffoux F. Calvo M. Tulliez S. Giraudier Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate Br J Haematol 120 2003 1091 1092
91. L. Legros J.P. Cassuto J.P. Ortonne Imatinib mesilate (Glivec): A systemic depigmenting agent for extensive vitiligo? Br J Dermatol 153 2005 691 692
92. J.M. Grichnik J.A. Burch J. Burchette C.R. Shea The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis J Invest Dermatol 111 1998 233 238
93. G. Etienne P. Cony-Makhoul F.X. Mahon Imatinib mesylate and gray hair N Engl J Med 347 2002 446
94. K. Prabhash G. Biswas N. Prasad N. Karant P.S. Sastry P.M. Parikh Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia Indian J Dermatol Venereol Leprol 72 2006 63 64
95. J. Dalmau L. Peramiquel L. Puig M.T. Fernandez-Figueras E. Roe A. Alomar Imatinib-associated lichenoid eruption: Acitretin treatment allows maintained antineoplastic effect Br J Dermatol 154 2006 1213 1216
96. P. Ena F. Chiarolini G.M. Siddi A. Cossu Oral lichenoid eruption secondary to imatinib (Glivec) J Dermatol Treat 15 2004 253 255
97. D. Lim J. Muir Lichenoid eruption to STI 571 Am J Hematol 70 2002 179
98. D.S. Lim J. Muir Oral lichenoid reaction to imatinib (STI 571, Gleevec) Dermatology 205 2002 169 171
99. C. Roux A.M. Boisseau-Garsaud I. Saint-Cyr R. Helenon D. Quist C. Delaunay Lichenoid cutaneous reaction to imatinib [in French] Ann Dermatol Venereol 131 6-7 pt 1 2004 571 573
100. S.H. Clark M. Duvic V.G. Prieto Mycosis fungoides-like reaction in a patient treated with Gleevec J Cutan Pathol 30 2003 279 281
101. F. Jardin P. Courville P. Lenain B. Lenormand S. Pouplin N. Contentin Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: Role of a T-cell clone induced by imatinib Lancet Oncol 6 2005 728 729
102. T. Yanagi D. Sawamura H. Shimizu Follicular mucinosis associated with imatinib (STI571) Br J Dermatol 151 2004 1276 1278
103. V. Brazzelli F. Prestinari E. Roveda T. Barbagallo E. Bellani C. Vassallo Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases J Am Acad Dermatol 53 5 suppl. 1 2005 S240 S243
104. E. Pasmatzi A. Monastirli P. Matsouka D. Tsambaos Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate Acta Derm Venereol 83 2003 391 392
105. D. Liu K. Seiter T. Mathews C.J. Madahar T. Ahmed Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate Leuk Res 28 suppl 1 2004 S61 S63
106. S.J. Ayirookuzhi L. Ma P. Ramshesh G. Mills Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia Arch Dermatol 141 2005 368 370
107. E.G. Dib J.J. Ifthikharuddin G.A. Scott S.R. Partilo Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy Leuk Res 29 2005 233 234
108. K. Van de Voorde H. De Raeve N. Van Regenmortel J. Lambert Imatinib-induced eccrine squamous syringometaplasia J Am Acad Dermatol 55 suppl 2 2006 S58 S59
109. N. Banka M. Aljurf I. Hamadah Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign Dermatology 207 2003 329 330
110. K. Shimizu H. Kuroda M. Kida H. Watanabe S. Shirao T. Akiyama Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia [in Japanese] Rinsho Ketsueki 46 2005 1152 1155
111. N. Deguchi T. Kawamura A. Shimizu R. Kitamura M. Yanagi N. Shibagaki Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia Br J Dermatol 154 2006 1216 1218
112. M. Breccia R. Latagliata I. Carmosino F. Mandelli G. Alimena Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia Leukemia 18 2004 182
113. M.W. Bekkenk M.H. Vermeer C.J. Meijer P.M. Jansen J.M. Middeldorp S.J. Stevens EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate Blood 102 2003 4243
114. T. O'Hare D.K. Walters E.P. Stoffregen T. Jia P.W. Manley J. Mestan In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 2005 4500 4505
115. M.R. Burgess B.J. Skaggs N.P. Shah F.Y. Lee C.L. Sawyers Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance Proc Natl Acad Sci U S A 102 2005 3395 3400
116. P.P. Piccaluga S. Paolini G. Martinelli Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia Cancer 110 2007 1178 1186
117. E. Weisberg P. Manley J. Mestan S. Cowan-Jacob A. Ray J.D. Griffin Nnilotinib: A novel and selective inhibitor of BCR-ABL Br J Cancer 94 2006 1765 1769
118. M. Talpaz N.P. Shah H. Kantarjian N. Donato J. Nicoll R. Paquette Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2006 2531 2541
119. A. Hochhaus H.M. Kantarjian M. Baccarani J.H. Lipton J.F. Apperley B.J. Druker Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood 109 2007 2303 2309
120. Sprycel package insert. Bristol-Meyers Squibb, New York, NY. Available from: http://www.fda.gov/cder/foi/label/2006/021986lbl.pdf [Accessed January 6, 2008].
121. S. Assouline P. Laneuville C. Gambacorti-Passerini Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia N Engl J Med 354 2006 2623 2624
122. F. Radaelli S. Bramanti N.N. Fantini G. Fabio I. Greco G. Lambertenghi-Deliliers Dasatinib-related alveolar pneumonia responsive to corticosteroids Leuk Lymphoma 47 2006 1180 1181
123. H. Kantarjian F. Giles L. Wunderle K. Bhalla S. O'Brien B. Wassman Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2006 2542 2551
124. H.M. Kantarjian F. Giles N. Gattermann K. Bhalla G. Alimena F. Palandri Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 2007 3540 3546
125. P. Erhardt E.J. Schremser G.M. Cooper B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway Mol Cell Biol 19 1999 5308 5315
126. A. Schulze K. Lehmann H.B. Jefferies M. McMahon J. Downward Analysis of the transcriptional program induced by Raf in epithelial cells Genes Dev 159 2001 81 94
127. J. Zhong J. Troppmair U.R. Rapp Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria Oncogene 20 2001 4807 4816
128. S.M. Wilhelm C. Carter L. Tang D. Wilkie A. McNabola H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
129. O. Hahn W. Stadler Sorafenib Curr Opin Oncol 18 2006 615 621
130. H. Richly P. Kupsch K. Passage M. Grubert R.A. Hilger R. Voigtmann Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer Int J Clin Pharmacol Ther 42 2004 650 651
131. T. Eisen T. Ahmad K.T. Flaherty M. Gore S. Kaye R. Marais Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis Br J Cancer 95 2006 581 586
132. L.L. Siu A. Awada C.H. Takimoto M. Piccart B. Schwartz T. Giannaris Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer Clin Cancer Res 12 2006 144 151
133. P. Kupsch B.F. Henning K. Passarge H. Richly K. Wiesemann R.A. Hilger Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer Clin Colorectal Cancer 5 2005 188 196
134. J.W. Clark J.P. Eder D. Ryan C. Lathia H.J. Lenz Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors Clin Cancer Res 11 2005 5472 5480
135. H. Richly B.F. Henning P. Kupsch K. Passarge M. Grubert R.A. Hilger Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors Ann Oncol 17 2006 866 873
136. D. Strumberg D. Voliotis J.G. Moeller R.A. Hilger H. Richly S. Kredtke Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors Int J Clin Pharmacol Ther 40 2002 580 581
137. M.J. Ratain T. Eisen W.M. Stadler K.T. Flaherty S.B. Kaye G.L. Rosner Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 2505 2512
138. B.P. Schneider K.D. Miller Angiogenesis of breast cancer J Clin Oncol 23 2005 1782 1790
139. W. Fiedler H. Serve H. Dohner M. Schwittay O.G. Ottmann A.M. O'Farrell A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease Blood 105 2005 986 993
140. A.M. O'Farrell J.M. Foran W. Fiedler H. Serve R.L. Paquette M.A. Cooper An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients Clin Cancer Res 9 2003 5465 5476
141. D.W. Kim Y.S. Jo H.S. Jung H.K. Chung J.H. Song K.C. Park An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases J Clin Endocrinol Metab 91 2006 4070 4076
142. S. Faivre C. Delbaldo K. Vera C. Robert S. Lozahic N. Lassau Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 2006 25 35
143. L. Rosen M. Mulay J. Long Phase I trial of SU11248, a novel tyrosine kinase inhibitor in advanced solid tumors (abstract) Proc Am Soc Clin Oncol 22 2003 765a
144. R.J. Motzer M.D. Michaelson B.G. Redman G.R. Hudes G. Wilding R.A. Figlin Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 16 24
145. C. Robert S. Faivre E. Raymond J.P. Armand B. Escudier Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 143 2005 313 314
146. K. Wu F. Heule K. Lam P. Sonneveld Pleomophic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma J Am Acad Dermatol 55 2006 897 900
147. J. Gerecitano A. Goy J. Wright B. MacGregor-Cortelli E. Neylon M. Gonen Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response? Br J Haematol 134 2006 391 398
148. L. Knoops A. Jacquemain D. Tennstedt I. Theate A. Ferrant E. van de Neste Bortezomib-induced Sweet syndrome Br J Haematol 131 2005 142
149. N. Van Regenmortel K. Van de Voorde H. De Raeve S. Rombouts A. Van de Velde J. Lambert Bortezomib-induced Sweet's síndrome Haematologica 90 suppl 12 2005 ECR43
150. M.A. Ozcan I. Alacacioglu O. Piskin B. Lebe N. Turgut S. Ceneli Bortezomib-induced skin lesion Acta Haematologica 116 2006 226 227
151. K. Ramadan K. McKenna T. Morris Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma Lancet Oncol 7 2006 958 959
152. D.F. Battafarano G.C. Zimmerman S.A. Older J.H. Keeling H.A. Burris Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases Cancer 76 1995 110 115
153. E. Espinosa P. Zamora J. Feliu M. Gonzalez Baron Classification of anticancer drugs—A new system based on therapeutic targets Cancer Treat Rev 29 2003 515 523
154. J.E. Cortes R. Pazdur Docetaxel J Clin Oncol 13 1995 2643 2655
155. G.C. Zimmerman J.H. Keeling H.A. Burris G. Cook R. Irvin J. Kuhn Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent Arch Dermatol 131 1995 202 206
156. M. Katoh M. Kadota Y. Nishimura A case of docetaxel-induced erythrodysesthesia J Dermatol 31 2004 403 406
157. W. Scheithauer J. Blum Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine Oncology (Williston Park) 18 2004 1161 1168
158. J. Childress J. Lokich Cutaneous hand and foot toxicity associated with cancer chemotherapy Am J Clin Oncol 26 2003 435 436
159. K.A. Remlinger Cutaneous reactions to chemotherapy drugs: The art of consultation Arch Dermatol 139 2003 77 81
160. E. Nagore A. Insa O. Sanmartin Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management Am J Clin Dermatol 1 2000 225 234
161. D. Eich K. Scharffetter-Kochanek H.T. Eich I. Tantcheva-Poor T. Krieg Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer Am J Clin Oncol 25 2002 599 602
162. A. Karam J.P. Metges J.P. Labat J.P. Leroy G. Guillet Squamous syringometaplasia associated with docetaxel Br J Dermatol 146 2002 524 525
163. G.C. Zimmerman J.H. Keeling M. Lowry J. Medina D.D. Von Hoff H.A. Burris Prevention of docetaxel-induced erythrodysesthesia with local hypothermia J Natl Cancer Inst 86 1994 557 558
164. C.Y. Chu C.H. Yang C.Y. Yang G.H. Hsiao H.C. Chiu Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel Br J Dermatol 142 2000 808 811
165. I.S. Woo K.H. Shim G.Y. Kim M.A. Lee J.H. Kang Y.S. Hong Nail changes during docetaxel containing combination chemotherapy Korean J Intern Med 19 2004 132 133
166. O. Correia C. Azevedo E. Pinto Ferreira F. Braga Cruz J. Polonia Nail changes secondary to docetaxel (Taxotere) Dermatology 198 1999 288 290
167. J.M. Extra F. Rousseau R. Bruno M. Clavel N. Le Bail M. Marty Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion Cancer Res 53 1993 1037 1042
168. M.G. Cleveland B.S. Ajaikumar R. Reganti Cutaneous fibrosis induced by docetaxel: A case report Cancer 88 2000 1078 1081
169. G. Hassett P. Harnett N. Manolios Scleroderma in association with the use of docetaxel (taxotere) for breast cancer Clin Exp Rheumatol 19 2001 197 200
170. M. Chen A.N. Crowson M. Woofter M.B. Luca C.M. Magro Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: Report of 4 cases J Rheumatol 31 2004 818 820
171. J.A. Ascherman S.L. Knowles K. Attkiss Docetaxel (taxotere) extravasation: A report of five cases with treatment recommendations Ann Plast Surg 45 2000 438 441
172. C.H. Ho C.H. Yang C.Y. Chu Vesicant-type reaction due to docetaxel extravasation Acta Derm Venereol 83 2003 467 468
173. R. Pazdur A.P. Kudelka J.J. Kavanagh P.R. Cohen M.N. Raber The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere) Cancer Treat Rev 19 1993 351 386
174. E.K. Rowinsky E.A. Eisenhauer V. Chaudhry S.G. Arbuck R.C. Donehower Clinical toxicities encountered with paclitaxel (Taxol) Semin Oncol 20 4 suppl. 3 1993 1 15
175. T. Shenkier K. Gelmon Paclitaxel and radiation-recall dermatitis J Clin Oncol 12 1994 439
176. C. Bokemeyer C. Lampe M. Heneka M. Schabet M. Bamberg L. Kanz Paclitaxel-induced radiation recall dermatitis Ann Oncol 7 1996 755 756
177. M.J. McCarty M.F. Peake P. Lillis S.J. Vukelja Paclitaxel-induced radiation recall dermatitis Med Pediatr Oncol 27 1996 185 186
178. J.Y. Payne F. Holmes P.R. Cohen R. Gagel A. Buzdar K. Dhingra Paclitaxel: Severe mucocutaneous toxicity in a patient with hyperbilirubinemia South Med J 89 1996 542 545
179. C.J. Link Jr. G.A. Sarosy E.C. Kohn M.C. Christian P. Davis D.O. Adamo Cutaneous manifestations of Taxol therapy Invest New Drugs 13 1995 261 263
180. D. de Argila J.D. Dominguez L. Iglesias Taxol-induced acral erythema Dermatology 192 1996 377 378
181. J.M. Weinberg C.L. Egan I.A. Tangoren L.J. Li K.A. Laughinghouse C.A. Guzzo Generalized pustular dermatosis following paclitaxel therapy Int J Dermatol 36 1997 559 560
182. P.C. Young A.D. Montemarano N. Lee P. Sau R.B. Weiss W.D. James Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption J Am Acad Dermatol 34 2 pt 1 1996 313 314
183. E.N. Ilyas G. Grana J.J. Green Inflammatory actinic keratoses secondary to systemic chemotherapy Cutis 75 2005 167 168
184. A. Hiraki K. Aoe T. Murakami T. Maeda R. Eda H. Takeyama Stevens–Johnson syndrome induced by paclitaxel in a patient with squamous cell carcinoma of the lung: A case report Anticancer Res 24 2C 2004 1135 1137
185. A.D. Cohen W. Mermershtain D.B. Geffen N. Schoenfeld R. Mamet E. Cagnano Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins J Dermatolog Treat 16 2005 19 21
186. I. Kupfer X. Balguerie P. Courville P. Chinet P. Joly Scleroderma-like cutaneous lesions induced by paclitaxel: A case study J Am Acad Dermatol 48 2003 279 281
187. P. Fumoleau F.M. Delgado T. Delozier A. Monnier M.A. Gil Delgado P. Kerbrat Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy J Clin Oncol 11 1993 1245 1252
188. P.M. Hoff V. Valero N. Ibrahim J. Willey G.N. Hortobagyi Hand-foot syndrome following prolonged infusion of high doses of vinorelbine Cancer 82 1998 965 969
189. M.J. Moreno de Vega E. Dauden P. Abajo B. Bartolome J. Fraga A. Garcia-Diez Skin necrosis from extravasation of vinorelbine J Eur Acad Dermatol Venereol 16 2002 488 490
190. S. Cicchetti B. Jemec D.T. Gault Two case reports of vinorelbine extravasation: Management and review of the literature Tumori 86 2000 289 292
191. S.J. Wright L.E. Robertson S. O'Brien W. Plunkett M.J. Keating The role of fludarabine in hematological malignancies Blood Rev 8 1994 125 134
192. M.A. Hood R.S. Finley Fludarabine: A review DICP 25 1991 518 524
193. J.J. Kavanagh I.H. Krakoff G.P. Bodey Phase I study of fludarabine (2-fluoro-ara-AMP) Eur J Cancer Clin Oncol 21 1985 1009 1011
194. J.P.L. Nomdedeu R. Martino M. Montagut R. Mateu A. Domingo-Albos J. Soler J. Moragas Peculiar acral erythematous eruption after fludarabine treatment Biol Clin Hematol 17 1995 92 93
195. J.F. Rossi A. van Hoof K. de Boeck S.A. Johnson D. Bron C. Foussard Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia J Clin Oncol 22 2004 1260 1267
196. A.L. Appleton L. Sviland A.D. Pearson J. Wilkes M.A. Green A.J. Malcolm Diagnostic features of transfusion associated graft versus host disease J Clin Pathol 47 1994 541 546
197. J. Braess K. Reich S. Willert F. Strutz C. Neumann W. Hiddemann Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL) Ann Hematol 75 1997 227 230
198. M. Briz R. Cabrera I. Sanjuan R. Fores J.L. Diez M. Herrero Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia Br J Haematol 91 1995 409 411
199. Z.T. Maung A.C. Wood G.H. Jackson G.E. Turner A.L. Appleton P.J. Hamilton Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia Br J Haematol 88 1994 649 652
200. A. Bazarbachi H. Bachelez L. Dehen A. Delmer R. Zittoun L. Dubertret Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine Ann Oncol 6 1995 730 731
201. A.M. Powell S. Albert N. Oyama Y. Sakuma-Oyama B. Bhogal M.M. Black Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans J Eur Acad Dermatol Venereol 18 2004 360 364
202. C. Gooptu T.J. Littlewood P. Frith C.C. Lyon A.J. Carmichael S. Oliwiecki Paraneoplastic pemphigus: An association with fludarabine? Br J Dermatol 144 2001 1255 1261
203. C. Pott-Hoeck W. Hiddemann Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias Ann Oncol 6 1995 421 433
204. G.J. Anhalt Paraneoplastic pemphigus Adv Dermatol 12 1997 77 96
205. L.R. Kong C.F. Huang D. Hakimian D. Variakojis L. Klein T.M. Kuzel Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma Cancer 82 1998 957 964
206. Y. Chubar M. Bennett Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol Br J Haematol 122 2003 768 770
207. M.R. Grey N.G. Flanagan P.R. Kelsey Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution Clin Lab Haematol 22 2000 111 113
208. P. Meunier S. Castaigne J.N. Bastie O. Chosidow S. Aractingi Cutaneous reactions after treatment with 2-chlorodeoxyadenosine Acta Derm Venereol 76 1996 385 386
209. P.M. Hoff Practical considerations in the use of oral fluoropyrimidines Semin Oncol 30 3 suppl. 6 2003 88 92
210. M. Malet-Martino R. Martino Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review Oncologist 7 2002 288 323
211. S. Abushullaih E.D. Saad M. Munsell P.M. Hoff Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience Cancer Invest 20 2002 3 10
212. I.O. Kara B. Sahin M. Erkisi Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction Breast 15 2006 414 424
213. Y. Lassere P. Hoff Management of hand-foot syndrome in patients treated with capecitabine (Xeloda) Eur J Oncol Nurs 8 suppl 1 2004 S31 S40
214. P. Narasimhan S. Narasimhan I.F. Hitti M. Rachita Serious hand-and-foot syndrome in black patients treated with capecitabine: Report of 3 cases and review of the literature Cutis 73 2004 101 106
215. G.M. Wilkes D. Doyle Palmar-plantar erythrodysesthesia Clin J Oncol Nurs 9 2005 103 106
216. V. Piguet L. Borradori Pyogenic granuloma-like lesions during capecitabine therapy Br J Dermatol 147 6 2002 1270 1272
217. K.G. Lewis M.D. Lewis L. Robinson-Bostom T.D. Pan Inflammation of actinic keratoses during capecitabine therapy Arch Dermatol 140 2004 367 368
218. M.H. Schmid-Wendtner C.M. Wendtner M. Volkenandt V. Heinemann Clinical picture: Leopard-like vitiligo with capecitabine Lancet 358 2001 1575
219. G.Y. Chen Y.H. Chen M.M. Hsu C.J. Tsao W.C. Chen Onychomadesis and onycholysis associated with capecitabine Br J Dermatol 145 2001 521 522
220. J. Bastida C. Diaz-Cascajo S. Borghi Chemotherapy-induced acral erythema due to Tegafur Acta Derm Venereol 77 1997 72 73
221. S.A. Elasmar E.D. Saad P.M. Hoff Case report: Hand-foot syndrome induced by the oral fluoropyrimidine S-1 Jpn J Clin Oncol 31 2001 172 174
222. C. Camps J.J. Soler M.J. Godes C. Pujol M.I. Febrer Cutaneous toxicity by ftorafur, hand-foot or palmar-plantar erythrodysesthesia syndrome [in Spanish] Rev Clin Esp 188 1991 165 166
223. A. Jucgla G. Sais M. Navarro J. Peyri Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur Arch Dermatol 131 1995 364 365
224. L. Rios-Buceta G.F. Buezo P.F. Penas E. Dauden J. Fernandez-Herrera A. Garcia-Diez Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur Acta Derm Venereol 77 1997 80 81
225. Y.H. Won J.J. Seo S.J. Kim S.C. Lee I.K. Chun Knuckle pad-like keratoderma: A new cutaneous side reaction induced by tegafur Int J Dermatol 37 1998 315 317
226. F. Revenga Cutaneous side-effects caused by Tegafur Int J Dermatol 38 1999 955 957
227. G.Y. Chen S.C. Chao W. Chen Black lunula caused by Tegafur Acta Derm Venereol 84 2004 238 239
228. E. Llistosella A. Codina R. Alvarez R.M. Pujol J.M. de Moragas Tegafur-induced acral hyperpigmentation Cutis 48 1991 205 207
229. A. Usuki Y. Funasaka M. Oka M. Ichihashi Tegafur-induced photosensitivity—Evaluation of provocation by UVB irradiation Int J Dermatol 36 1997 604 606
230. K. Kawamura T. Tsuji Y. Kuwabara Mucha–Habermann disease-like eruptions due to Tegafur J Dermatol 26 1999 164 167
231. C. Manegold P. Zatloukal K. Krejcy J. Blatter Gemcitabine in non-small cell lung cancer (NSCLC) Invest New Drugs 18 2000 29 42
232. S. Okuno J. Edmonson M. Mahoney J.C. Buckner S. Frytak E. Galanis Phase II trial of gemcitabine in advanced sarcomas Cancer 94 2002 3225 3229
233. V. Heinemann Role of gemcitabine in the treatment of advanced and metastatic breast cancer Oncology 64 2003 191 206
234. C.Y. Chu C.H. Yang H.C. Chiu Gemcitabine-induced acute lipodermatosclerosis-like reaction Acta Derm Venereol 81 2001 426 428
235. G. Bar-Sela A. Beny R. Bergman A. Kuten Gemcitabine-induced radiation recall dermatitis: Case report Tumori 87 2001 428 430
236. H.J. Burstein Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine J Clin Oncol 18 2000 693 694
237. D. Castellano R. Hitt H. Cortes-Funes A. Romero J.L. Rodriguez-Peralto Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine J Clin Oncol 18 2000 695 696
238. B.M. Schwartz D. Khuntia A.W. Kennedy M. Markman Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy Gynecol Oncol 91 2003 421 422
239. M.G. Fakih Gemcitabine-induced rectus abdominus radiation recall JOP 7 2006 306 310
240. G. Fogarty D. Ball D. Rischin Radiation recall reaction following gemcitabine Lung Cancer 33 2001 299 302
241. M.D. Jeter P.A. Janne S. Brooks H.J. Burstein P. Wen C.S. Fuchs Gemcitabine-induced radiation recall Int J Radiat Oncol Biol Phys 53 2002 394 400
242. J. del Pozo W. Martinez M.T. Yebra-Pimentel M. Almagro C. Pena-Penabad E. Fonseca Linear immunoglobulin A bullous dermatosis induced by gemcitabine Ann Pharmacother 35 2001 891 893
243. D. Bessis B. Guillot E. Legouffe J.J. Guilhou Gemcitabine-associated scleroderma-like changes of the lower extremities J Am Acad Dermatol 51 suppl 2 2004 S73 S76
244. F. Zustovich P. Pavei G. Cartei Erysipeloid skin toxicity induced by gemcitabine J Eur Acad Dermatol Venereol 20 2006 757 758
245. A. Brandes U. Reichmann L. Plasswilm M. Bamberg Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine—A report of three cases Anticancer Drugs 11 2000 15 17
246. I. Kuku E. Kaya A. Sevinc I. Aydogdu Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma J Eur Acad Dermatol Venereol 16 2002 271 272
247. + pseudolymphoma Br J Dermatol 145 2001 650 652
248. K.R. Sommers K.M. Kong D.T. Bui J.P. Fruehauf R.F. Holcombe Stevens–Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine Anticancer Drugs 14 2003 659 662
249. C.Y. Chu C.H. Yang H.C. Chiu Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment Acta Derm Venereol 82 2002 147 148
250. R. Thodtmann T. Sauter S. Weinknecht L. Weissbach J. Blatter U. Ohnmacht A phase II trial of pemetrexed in patients with metastatic renal cancer Invest New Drugs 21 2003 353 358
251. A.A. Adjei C. Erlichman J.A. Sloan J.M. Reid H.C. Pitot R.M. Goldberg Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors J Clin Oncol 18 2000 1748 1757
252. M.H. Cohen J.R. Johnson Y.C. Wang R. Sridhara R. Pazdur FDA drug approval summary: Pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer Oncologist 10 2005 363 368
253. J. Hureaux Y. Le Guen C. Tuchais L. Savary T. Urban Radiation recall dermatitis with pemetrexed Lung Cancer 50 2005 255 258
254. F. Barlési C. Tummino A.M. Tasei P. Astoul Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis Lung Cancer 54 2006 423 425
255. G. Lopes V. Vincek L.E. Raez Pemetrexed-associated urticarial vasculitis Lung Cancer 51 2006 247 249
256. R.S. Go A.A. Adjei Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin J Clin Oncol 17 1999 409 422
257. A.J. Wagstaff A. Ward P. Benfield R.C. Heel Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer Drugs 37 1989 162 190
258. L. Meyer T. Zuberbier M. Worm H. Oettle H. Riess Hypersensitivity reactions to oxaliplatin: Cross-reactivity to carboplatin and the introduction of a desensitization schedule J Clin Oncol 20 2002 1146 1147
259. M. Markman A. Kennedy K. Webster P. Elson G. Peterson B. Kulp Clinical features of hypersensitivity reactions to carboplatin J Clin Oncol 17 1999 1141
260. J.L. Malo Occupational rhinitis and asthma due to metal salts Allergy 60 2005 138 139
261. M. Markman K. Zanotti B. Kulp G. Peterson M. Markman Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity Gynecol Oncol 89 2003 514 516
262. K.M. Zanotti L.A. Rybicki A.W. Kennedy J.L. Belinson K.D. Webster B. Kulp Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy J Clin Oncol 19 2001 3126 3129
263. J. Menczer G. Barda M. Glezerman H. Hyat Y. Brenner C.M. Brickman Hypersensitivity reaction to carboplatin. Results of skin tests Eur J Gynaecol Oncol 20 1999 214 216
264. M. Navo A. Kunthur M.L. Badell L.W. Coffer 2nd M. Markman J. Brown Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients Gynecol Oncol 103 2006 608 613
265. R. Confino-Cohen A. Fishman M. Altaras A. Goldberg Successful carboplatin desensitization in patients with proven carboplatin allergy Cancer 104 2005 640 643
266. M. Libra R. Sorio A. Buonadonna M. Berretta P. Stefanovski G. Toffoli Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases Tumori 89 2003 311 313
267. A. Ottaiano R. Tambaro S. Greggi R. Prato M. Di Maio G. Esposito Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma Anticancer Res 23 2003 3465 3468
268. J. Cassidy J.L. Misset Oxaliplatin-related side effects: Characteristics and management Semin Oncol 29 5 suppl. 15 2002 11 20
269. C. Garufi A. Cristaudo B. Vanni E. Bria A.M. Aschelter B. Santucci Skin testing and hypersensitivity reactions to oxaliplatin Ann Oncol 14 2003 497 498
270. I. Gonzalez-Mahave T. Lobera Iabairu A. Blasco Sarramian M.D. del Pozo Gil M. Zorrilla E. Velez de Mendizábal Anaphylaxis produced by oxaliplatin J Investig Allergol Clin Immunol 15 2005 75 77
271. F. Maindrault-Goebel T. Andre C. Tournigand C. Louvet N. Perez-Staub N. Zeghib Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients Eur J Cancer 41 2005 2262 2267
272. M. Baur H.R. Kienzer T. Rath C. Dittrich Extravasation of Oxaliplatin (Eloxatin((R))) - Clinical Course Onkologie 23 2000 468 471
273. K.F. Foo M. Michael G. Toner J. Zalcberg A case report of oxaliplatin extravasation Ann Oncol 14 2003 961 962
274. M.L. de Lemos S. Walisser Management of extravasation of oxaliplatin J Oncol Pharm Pract 11 2005 159 162
275. R. Eckert K.P. Maier Necrotizing panniculitis after extravasation of oxaliplatin (abstract) Ann Oncol 13 suppl 5 2002 29
276. J.G. Kennedy J.P. Donahue B. Hoang P.J. Boland Vesicant characteristics of oxaliplatin following antecubital extravasation Clin Oncol (R Coll Radiol) 15 2003 237 239
277. R.T. Chan G.K. Au J.W. Ho K.W. Chu Radiation recall with oxaliplatin: Report of a case and a review of the literature Clin Oncol (R Coll Radiol) 13 2001 55 57
278. F. Petit-Laurent T. Conroy I. Krakowski A. Barbaud P. Trechot Delayed urticaria with oxaliplatin [in French] Gastroenterol Clin Biol 24 2000 851 852
279. R. McMenemin G. Macdonald L. Moffat D. Bissett A phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: Tolerability and efficacy modification by liposomal encapsulation Invest New Drugs 20 2002 331 337
280. M. Theodoulou C. Hudis Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 100 2004 2052 2063
281. A. Gabizon D.C. Price J. Huberty R.S. Bresalier D. Papahadjopoulos Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies Cancer Res 50 1990 6371 6378
282. S.E. Krown D.W. Northfelt D. Osoba J.S. Stewart Use of liposomal anthracyclines in Kaposi's sarcoma Semin Oncol 31 6 suppl. 13 2004 36 52
283. F.M. Muggia J.D. Hainsworth S. Jeffers P. Miller S. Groshen M. Tan Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation J Clin Oncol 15 1997 987 993
284. A.M. Lopez L. Wallace R.T. Dorr M. Koff E.M. Hersh D.S. Alberts Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia Cancer Chemother Pharmacol 44 1999 303 306
285. J. Szebeni L. Baranyi S. Savay J. Milosevits R. Bunger P. Laverman Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: Experimental and clinical studies J Liposome Res 12 2002 165 172
286. A. Jimeno E.M. Ciruelos D. Castellano B. Caballero J.L. Rodriguez-Peralto H. Cortes-Funes Radiation recall dermatitis induced by pegylated liposomal doxorubicin Anticancer Drugs 14 2003 575 576
287. F.M. Muggia Re: ‘Radiation recall dermatitis induced by pegylated liposomal doxorubicin.’ Anticancer Drugs 15 2004 35
288. M. Lotem A. Hubert O. Lyass M.A. Goldenhersh A. Ingber T. Peretz Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin Arch Dermatol 136 2000 1475 1480
289. Y.F. Hui J.E. Cortes Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin Pharmacotherapy 20 2000 1221 1223
290. C. Gabel P.J. Eifel C. Tornos T.W. Burke Radiation recall reaction to idarubicin resulting in vaginal necrosis Gynecol Oncol 57 1995 266 269
291. D.J. Borecky J.J. Stephenson J.H. Keeling S.J. Vukelja Idarubicin-induced pigmentary changes of the nails Cutis 59 1997 203 204
292. S.W. Langer M. Sehested P.B. Jensen Treatment of anthracycline extravasation with dexrazoxane Clin Cancer Res 6 2000 3680 3686
293. C.M. Rocha Lima A. Chiappori Treatment of relapsed small-cell lung cancer—A focus on the evolving role of topotecan Lung Cancer 40 2003 229 236
294. K. Seiter Toxicity of the topoisomerase I inhibitors Expert Opin Drug Saf 4 2005 45 53
295. G.J. Creemers J. Wanders T. Gamucci S. Vallentin L.Y. Dirix P. Schoffski Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group Ann Oncol 6 1995 844 846
296. E.K. Rowinsky L.B. Grochow C.B. Hendricks D.S. Ettinger A.A. Forastiere L.A. Hurowitz Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor J Clin Oncol 10 1992 647 656
297. M. Marini D. Wright M. Ropolo M. Abbruzzese G. Casas Neutrophilic eccrine hidradenitis secondary to topotecan J Dermatolog Treat 13 2002 35 37
298. C. Bachmeyer P. Chaibi S. Aractingi Neutrophilic eccrine hidradenitis induced by granulocyte colony-stimulating factor Br J Dermatol 139 1998 354 355
299. M.L. Rothenberg J.V. Cox R.F. DeVore J.D. Hainsworth R. Pazdur S.E. Rivkin A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma Cancer 85 1999 786 795